Zobrazeno 1 - 10
of 132
pro vyhledávání: '"Joy C Yang"'
Autor:
Bo Chen, William Murphy, Pengfei Xu, Chengfei Liu, Joy C Yang, Christopher Nip, Christopher P Evans, Leyi Wang, Jonathan EVan Dyke
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/0bf9acbb33b04596bda11be828834d66
Autor:
Bo Chen, William J Murphy, Xiong Zhang, Pengfei Xu, Chengfei Liu, Joy C Yang, Christopher Nip, Jonathan E Van Dyke, Hong-Wu Chen, Christopher P Evans
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 5 (2023)
Background Emerging data suggest that patients with enzalutamide-treated prostate cancer with increased programmed death-ligand 1 (PD-L1) expression may benefit from anti-PD-L1 treatment. Unfortunately, the Phase III IMbassador250 clinical trial reve
Externí odkaz:
https://doaj.org/article/8f5213ee1f4342c4a2bb4d14ef4772c7
Autor:
Wenchang Guo, Ruiwu Liu, Gaurav Bhardwaj, Ai-Hong Ma, Chun Changou, Joy C Yang, Yuanpei Li, Caihong Feng, Yan Luo, Anisha Mazloom, Eduardo Sanchez, Yan Wang, Wenzhe Huang, Randen Patterson, Christopher P Evans, Kit S Lam, Hsing-Jien Kung
Publikováno v:
PLoS ONE, Vol 8, Iss 8, p e70910 (2013)
Etk is a non-receptor tyrosine kinase, which provides a strong survival signal in human prostate cancer cells. Src, another tyrosine kinase that cross-activates with Etk, has been shown to play an important role in prostate cancer metastasis. Herein,
Externí odkaz:
https://doaj.org/article/847de7c6ffd142fb90d6021c6ca3066d
Autor:
Chengfei Liu, Wei Lou, Joy C. Yang, Liangren Liu, Cameron M. Armstrong, Alan P. Lombard, Ruining Zhao, Onika D. V. Noel, Clifford G. Tepper, Hong-Wu Chen, Marc Dall’Era, Christopher P. Evans, Allen C. Gao
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-16 (2018)
The AR-V7 isoform is associated with anti-androgen drug resistance in prostate cancer. Here, the authors show that AR-V7 protein stability is regulated by HSP70/STUB1 complex-mediated proteostasis which confers drug resistance in late stage prostate
Externí odkaz:
https://doaj.org/article/a5238e051d1c4725877bc665524a75c3
Autor:
Joy C. Yang, Pengfei Xu, Shu Ning, Logan J. Wasielewski, Hans Adomat, Sung Hee Hwang, Christophe Morisseau, Martin Gleave, Eva Corey, Allen C. Gao, Primo N. Lara Jr, Christopher P. Evans, Bruce D. Hammock, Chengfei Liu
Publikováno v:
Oncogene
Oncogene, vol 42, iss 9
Oncogene, vol 42, iss 9
Castration-resistant prostate cancer (CRPC) is the main driving force of mortality in prostate cancer patients. Among the parameters contributing to the progression of CRPC and treatment failure, elevation of the steroidogenic enzyme AKR1C3 and andro
Autor:
Shu Ning, Chengfei Liu, Wei Lou, Joy C. Yang, Alan P. Lombard, Leandro S. D'Abronzo, Neelu Batra, Ai-Ming Yu, Amy R. Leslie, Masuda Sharifi, Christopher P. Evans, Allen C. Gao
Publikováno v:
Molecular cancer therapeutics, vol 21, iss 10
Mol Cancer Ther
Mol Cancer Ther
The next-generation antiandrogen drugs such as enzalutamide and abiraterone extend survival times and improve quality of life in patients with advanced prostate cancer. However, resistance to both drugs occurs frequently through mechanisms that are i
Autor:
Allen C. Gao, Christopher P. Evans, Leandro S. D'Abronzo, Alan P. Lombard, Binhao Zou, Xiaomin Qiu, Liangren Liu, Wei Lou, Cameron M. Armstrong, Joy C. Yang, Chengfei Liu
Supplemental Figure 1: C4-2B parental and C4-2B MDVR tumors were processed and whole tumor lysates were extracted and subjected to western blot; Supplemental Figure 2: The KLK3 mRNA expression and PSA expression in C4-2B parental and C4-2B MDVR cells
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::393fcc0da90d650d5db72e84a8be6a9e
https://doi.org/10.1158/1535-7163.22505649
https://doi.org/10.1158/1535-7163.22505649
Autor:
Allen C. Gao, Christopher P. Evans, Leandro S. D'Abronzo, Alan P. Lombard, Binhao Zou, Xiaomin Qiu, Liangren Liu, Wei Lou, Cameron M. Armstrong, Joy C. Yang, Chengfei Liu
The mechanisms resulting in resistance to next-generation antiandrogens in castration-resistant prostate cancer are incompletely understood. Numerous studies have determined that constitutively active androgen receptor (AR) signaling or full-length A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d72263993a3830af26902a7899d471db
https://doi.org/10.1158/1535-7163.c.6538143.v1
https://doi.org/10.1158/1535-7163.c.6538143.v1
Autor:
Allen C. Gao, Christopher P. Evans, Masuda Sharifi, Amy R. Leslie, Ai-Ming Yu, Neelu Batra, Leandro S. D'Abronzo, Alan P. Lombard, Joy C. Yang, Wei Lou, Chengfei Liu, Shu Ning
Supplementary Data from Bioengineered BERA-Wnt5a siRNA Targeting Wnt5a/FZD2 Signaling Suppresses Advanced Prostate Cancer Tumor Growth and Enhances Enzalutamide Treatment
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::44862ad3721c003a0dbf4f662c85ba0d
https://doi.org/10.1158/1535-7163.22523499
https://doi.org/10.1158/1535-7163.22523499
Autor:
Christopher P. Evans, Allen C. Gao, Martin E. Gleave, Emma S. Tomlinson Guns, Hans H. Adomat, Chengfei Liu, Joy C. Yang, Vito Cucchiara
Hormone therapy is currently the mainstay in the management of locally advanced and metastatic prostate cancer. Degarelix (Firmagon), a gonadotropin-releasing hormone (GnRH) receptor antagonist differs from luteinizing hormone-releasing hormone (LHRH
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::341fa5d7c1bd08e07b1e186e57d38e03
https://doi.org/10.1158/1535-7163.c.6537793.v1
https://doi.org/10.1158/1535-7163.c.6537793.v1